Special population medication for Venetoclax
Venetoclax, as a BCL-2 inhibitor, needs to be adjusted according to physiological status and organ function when used in special populations. The following provides a detailed explanation of medication precautions for different populations such as pregnancy and lactation.
1. Pregnant women
(1) Prohibition principle: Animal studies have shown that Venetoclase has embryonic lethality and teratogenicity, and its use is prohibited during pregnancy.
(2) Risk assessment: Women of childbearing age need to confirm their pregnancy status before taking medication, and effective contraceptive measures should be taken during treatment and within 30 days after the last dose.
2. Lactating women
(1) Drug transfer risk: There is no data on drug concentration in breast milk, but it may be secreted into breast milk based on molecular characteristics.
(2) Medication recommendation: Breastfeeding should be suspended during the treatment period and within one week after the last dose to avoid exposure risks to the infant.
3. Child patients
(1) Age restriction: The safety and efficacy of using it for patients under 18 years old have not been established, and it is not recommended.
(2) Special case: Individualized evaluation and use under strict supervision of a hematology oncology specialist.
4. Elderly patients
(1) Dose adjustment: Patients aged 65 and above do not require routine dose reduction, but need to strengthen adverse reaction monitoring.
(2) Risk Warning: Elderly patients in clinical trials have a higher incidence of infection and neutropenia, and close monitoring of blood routine is necessary.
5. Patients with renal insufficiency
(1) Mild to moderate damage: No dose adjustment required, but renal function changes need to be monitored.
(2) Severe damage: End stage renal disease patients (CLcr<30mL/min) lack safety data and are advised to avoid use.
6. Patients with liver dysfunction
(1) Child Pugh classification: A/B patients require a 50% reduction, while C patients are contraindicated.
(2) Monitoring requirements: During the treatment period, liver function should be tested monthly. If jaundice or ALT>3 times ULN occurs, medication should be discontinued.
Disclaimer：《Special population medication for Venetoclax》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！